Primary Safety Endpoint Met in PROTECT trial

AI SummaryClose X

Allergy Therapeutics PLC announced that its Phase I/IIa PROTECT trial has met its primary safety endpoint, with preliminary data from 48 participants showing that a 2000-fold increase in the dose of VLP Peanut was safe and well-tolerated. The trial completed final dosing at the highest planned treatment dose, and data from a second interim biomarker analysis in peanut-allergic patients receiving these highest doses is anticipated in Q1 2026. Preparations are underway for a Phase IIb trial, informed by the safety and efficacy data from the PROTECT study.

Disclaimer*

UK 100

Latest directors dealings